PriceTargets.com logo

Portage Biotech - ATON Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.00
  • Forecasted Upside: 532.91%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.32 As of 04/2/2026 05:00 PM ET
▼ -0.0086 (-2.65%)

This chart shows the closing price for ATON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Portage Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATON

Analyst Price Target is $2.00
▲ +532.91% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Portage Biotech in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 532.91% upside from the last price of $0.32.

This chart shows the closing price for ATON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Portage Biotech. This rating has held steady since January 2026, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/24/2026HC WainwrightInitiated CoverageBuy$2.00
1/26/2026Weiss RatingsInitiated CoverageSell (E+)
(Data available from 4/2/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2026

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Portage Biotech logo
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More

Today's Range

Now: $0.32
Low: $0.30
High: $0.33

50 Day Range

MA: $0.44
Low: $0.30
High: $0.74

52 Week Range

Now: $0.32
Low: $0.29
High: $15.82

Volume

564,645 shs

Average Volume

5,770,781 shs

Market Capitalization

$7.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Portage Biotech?

The following Wall Street analysts have issued stock ratings on Portage Biotech in the last year: HC Wainwright, and Weiss Ratings.
View the latest analyst ratings for ATON.

What is the current price target for Portage Biotech?

0 Wall Street analysts have set twelve-month price targets for Portage Biotech in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 547.2%. HC Wainwright has the highest price target set, predicting ATON will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Portage Biotech in the next year.
View the latest price targets for ATON.

What is the current consensus analyst rating for Portage Biotech?

Portage Biotech currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATON, but not buy more shares or sell existing shares.
View the latest ratings for ATON.

What other companies compete with Portage Biotech?

Other companies that are similar to Portage Biotech include Briacell Therap, Promis Neurosciences, Aytu BioPharma, BGM Group and Kyntra Bio. Learn More about companies similar to Portage Biotech.

How do I contact Portage Biotech's investor relations team?

Portage Biotech's physical mailing address is 6 ADELAIDE ST. EAST, SUITE 300, TORONTO, Ontario, Canada, M5C 1H6. The company's listed phone number is (416) 737-7600 and its investor relations email address is [email protected]. The official website for Portage Biotech is portagebiotech.com. Learn More about contacing Portage Biotech investor relations.